{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:57:47Z","timestamp":1784185067532,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1245\/s10434-025-18086-y","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T15:26:35Z","timestamp":1755703595000},"page":"9825-9835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Biology is Queen: The Oncotype DX 21-Gene Recurrence Score Has Stronger Prognostic Ability than Lymph Node Burden for Patients with Breast Cancer"],"prefix":"10.1245","volume":"32","author":[{"given":"Chelsea","family":"Marin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myla","family":"Strawderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derick","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Gooch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly R.","family":"Gergelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"O\u2019Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"issue":"4","key":"18086_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/00000421-198208000-00005","volume":"5","author":"DL Ahmann","year":"1982","unstructured":"Ahmann DL, O\u2019Fallon JR, Scanlon PW, Payne WS, Bisel HF, Edmonson JH, et al. A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. Am J Clin Oncol. 1982;5(4):371\u201381.","journal-title":"Am J Clin Oncol."},{"issue":"3","key":"18086_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/00000658-199709000-00007","volume":"226","author":"EC Dees","year":"1997","unstructured":"Dees EC, Shulman LN, Souba WW, Smith BL. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection. Ann Surg. 1997;226(3):279\u201386.","journal-title":"Ann. Surg."},{"issue":"4","key":"18086_CR3","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/sj.bjc.6601150","volume":"89","author":"F Peintinger","year":"2003","unstructured":"Peintinger F, Reitsamer R, Stranzl H, Ralph G. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br J Cancer. 2003;89(4):648\u201352.","journal-title":"Br J Cancer."},{"issue":"10","key":"18086_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927\u201333.","journal-title":"Lancet Oncol."},{"issue":"4","key":"18086_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u201301): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297\u2013305.","journal-title":"Lancet Oncol."},{"issue":"1","key":"18086_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1245\/s10434-012-2569-y","volume":"20","author":"M Sola","year":"2013","unstructured":"Sola M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048\/13\/2000. Ann Surg Oncol. 2013;20(1):120\u20137.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"18086_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569\u201375.","journal-title":"JAMA."},{"issue":"12","key":"18086_CR8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310.","journal-title":"Lancet Oncol."},{"issue":"4","key":"18086_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","volume":"43","author":"A Savolt","year":"2017","unstructured":"Savolt A, Peley G, Polgar C, Udvarhelyi N, Rubovszky G, Kovacs E, et al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla - surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43(4):672\u20139.","journal-title":"Eur J Surg Oncol."},{"issue":"27","key":"18086_CR10","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817\u201326.","journal-title":"N Engl J Med."},{"issue":"21","key":"18086_CR11","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","volume":"373","author":"JA Sparano","year":"2015","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373(21):2005\u201314.","journal-title":"N Engl J Med."},{"issue":"2","key":"18086_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111\u201321.","journal-title":"N Engl J Med."},{"issue":"25","key":"18086_CR13","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347.","journal-title":"N Engl J Med."},{"issue":"1","key":"18086_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77\u201390.","journal-title":"Lancet Oncol."},{"issue":"13","key":"18086_CR15","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.1245\/s10434-023-14245-1","volume":"30","author":"C Farley","year":"2023","unstructured":"Farley C, Bassett R, Meric-Bernstam F, Bedrosian I, Caudle A, DeSnyder S, et al. To dissect or not to dissect: can we predict the presence of four or more axillary lymph node metastases in postmenopausal women with clinically node-negative breast cancer? Ann Surg Oncol. 2023;30(13):8327\u201334.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"18086_CR16","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1200\/JCO.2007.11.9479","volume":"26","author":"A Katz","year":"2008","unstructured":"Katz A, Smith BL, Golshan M, Niemierko A, Kobayashi W, Raad RA, et al. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol. 2008;26(13):2093\u20138.","journal-title":"J Clin Oncol."},{"issue":"12","key":"18086_CR17","doi-asserted-by":"publisher","first-page":"7674","DOI":"10.1245\/s10434-022-12032-y","volume":"29","author":"O Kantor","year":"2022","unstructured":"Kantor O, Weiss A, Burstein HJ, Mittendorf EA, King TA. Sentinel lymph node biopsy alone is adequate for chemotherapy decisions in postmenopausal early-stage hormone-receptor-positive, HER2-negative breast cancer with one to three positive sentinel lymph nodes. Ann Surg Oncol. 2022;29(12):7674\u201382.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"18086_CR18","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1245\/s10434-022-12193-w","volume":"29","author":"M Pilewskie","year":"2022","unstructured":"Pilewskie M, Sevilimedu V, Eroglu I, Le T, Wang R, Morrow M, et al. How often do sentinel lymph node biopsy results affect adjuvant therapy decisions among postmenopausal women with early-stage HR(+)\/HER2(-) breast cancer in the post-RxPONDER era? Ann Surg Oncol. 2022;29(10):6267\u201373.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"18086_CR19","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","volume":"9","author":"OD Gentilini","year":"2023","unstructured":"Gentilini OD, Botteri E, Sangalli C, Galimberti V, Porpiglia M, Agresti R, et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the sound randomized clinical trial. JAMA Oncol. 2023;9(11):1557\u201364.","journal-title":"JAMA Oncol."},{"issue":"3","key":"18086_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamaoncol.2020.7320","volume":"7","author":"KF Hoskins","year":"2021","unstructured":"Hoskins KF, Danciu OC, Ko NY, Calip GS. Association of race\/ethnicity and the 21-gene recurrence score with breast cancer-specific mortality among US women. JAMA Oncol. 2021;7(3):370\u20138.","journal-title":"JAMA Oncol."},{"issue":"4","key":"18086_CR21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/jnci\/djaa148","volume":"113","author":"KS Albain","year":"2021","unstructured":"Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Wood WC, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW, Sparano JA. Race, ethnicity, and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. J Natl Cancer Inst. 2021;113(4):390\u20139.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"18086_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s12885-024-12238-1","volume":"24","author":"J Gill","year":"2024","unstructured":"Gill J, Yendamuri K, Chatterjee U, Yao S, Oladeru OT, Singh AK, Ma SJ. Racial\/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer. BMC Cancer. 2024;24(1):461.","journal-title":"BMC Cancer."},{"issue":"8","key":"18086_CR23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, van\u2019t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717\u201329.","journal-title":"N Engl J Med."},{"issue":"1","key":"18086_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41523-024-00653-3","volume":"10","author":"F Panet","year":"2024","unstructured":"Panet F, Papakonstantinou A, Borrell M, et al. Use of ctDNA in early breast cancer: analytical validity and clinical potential. NPJ Breast Cancer. 2024;10(1):50.","journal-title":"NPJ Breast Cancer."},{"issue":"2","key":"18086_CR25","doi-asserted-by":"publisher","first-page":"022703","DOI":"10.1117\/1.BIOS.2.2.022703","volume":"2","author":"TM Elias","year":"2025","unstructured":"Elias TM, Desa DE, Brown IV EB, Paul S, Ramirez GA, Turner BM, Madden KS, Gonzalez RS, Weiss A, Brown III EB. Exploring racial differences in second-harmonic-generation\u2013based prognostic indicators of metastasis in breast and colon cancer. Biophoton Discov. 2025;2(2):022703.","journal-title":"Biophoton. Discov."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18086-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18086-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18086-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:18:20Z","timestamp":1762352300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18086-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["18086"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18086-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ajay Dhakal reports paid consulting for Eli Lilly; research funding from Celcuity and Puma Biotechnology; and honoraria from OncLive (MJH Lifesciences), Gilead Sciences, AstraZeneca, WebMD\/Medscape, and Empire State Hematology & Oncology Society. Anna Weiss reports paid advisory board participation for Abbvie, Merck, and Myriad, and has received honoraria from OncLive (MJH Lifesciences), Empire State Hematology & Oncology Society, and the Society of Breast Imaging. Ruth O\u2019Regan reports advisory roles for Biotheranostics, Lilly, and Pfizer, and a Data Monitoring Committee role for Gilead. Chelsea Marin, Myla Strawderman, Derick Peterson, Zijing Cheng, Yue Li, Jessica C. Gooch, Kimberly R. Gergelis, Bradley Turner, and Edward B. Brown have no conflicts of interest to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}